To evaluate the efficacy and safety of moxibustion in treating cancer-related fatigue (CRF) in patients with gastrointestinal cancer, highlighting the significant impact of CRF on quality of life and treatment adherence.
Key Findings:
CRF significantly impacts quality of life and treatment adherence in gastrointestinal cancer patients, necessitating effective management strategies.
Moxibustion is a promising CAM therapy for CRF but lacks robust clinical evidence, indicating a need for further research.
Interpretation:
The trial aims to provide high-quality evidence on the effectiveness of moxibustion for alleviating CRF, potentially influencing treatment protocols for gastrointestinal cancer patients and improving patient outcomes.
Limitations:
Limited generalizability due to the specific patient population and treatment setting.
Potential biases in self-reported outcomes, which may affect the reliability of the results.
Conclusion:
This trial seeks to fill the gap in clinical evidence regarding moxibustion's role in managing CRF, with implications for improving patient care in gastrointestinal cancer and addressing a critical aspect of their treatment.
